Checkpoint Therapeutics (CKPT) Competitors $4.11 +0.01 (+0.24%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$4.10 -0.01 (-0.24%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CKPT vs. VERA, TVTX, GPCR, MESO, EVO, INDV, OCUL, CALT, AMPH, and ARDXShould you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Vera Therapeutics (VERA), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), Mesoblast (MESO), Evotec (EVO), Indivior (INDV), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Checkpoint Therapeutics vs. Vera Therapeutics Travere Therapeutics Structure Therapeutics Mesoblast Evotec Indivior Ocular Therapeutix Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Ardelyx Checkpoint Therapeutics (NASDAQ:CKPT) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Do institutionals and insiders believe in CKPT or VERA? 22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, CKPT or VERA? Checkpoint Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$41K8,396.83-$51.85M-$1.43-2.87Vera TherapeuticsN/AN/A-$95.99M-$2.75-8.50 Do analysts recommend CKPT or VERA? Checkpoint Therapeutics presently has a consensus price target of $4.33, suggesting a potential upside of 5.43%. Vera Therapeutics has a consensus price target of $64.67, suggesting a potential upside of 176.71%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20 Does the media prefer CKPT or VERA? In the previous week, Vera Therapeutics had 14 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 15 mentions for Vera Therapeutics and 1 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 1.87 beat Vera Therapeutics' score of 1.25 indicating that Checkpoint Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Checkpoint Therapeutics Very Positive Vera Therapeutics Positive Does the MarketBeat Community favor CKPT or VERA? Checkpoint Therapeutics received 141 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Vera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Is CKPT or VERA more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Vera Therapeutics N/A -50.13%-39.50% Which has more risk and volatility, CKPT or VERA? Checkpoint Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. SummaryVera Therapeutics beats Checkpoint Therapeutics on 9 of the 17 factors compared between the two stocks. Get Checkpoint Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CKPT vs. The Competition Export to ExcelMetricCheckpoint TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$344.27M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.237.4422.5718.48Price / Sales8,396.83242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book-8.746.516.774.25Net Income-$51.85M$143.21M$3.22B$248.23M7 Day Performance0.49%1.97%1.46%0.89%1 Month Performance1.73%6.89%3.98%3.53%1 Year Performance193.57%-2.52%16.14%5.09% Checkpoint Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CKPTCheckpoint Therapeutics2.4065 of 5 stars$4.11+0.2%$4.33+5.4%+195.7%$344.27M$41,000.00-2.2310Positive NewsVERAVera Therapeutics2.9227 of 5 stars$21.11-0.8%$64.67+206.3%-40.9%$1.35BN/A-8.0940Upcoming EarningsNews CoveragePositive NewsGap DownTVTXTravere Therapeutics2.8971 of 5 stars$15.11+1.3%$32.08+112.3%+276.3%$1.34B$233.18M-3.69460News CoveragePositive NewsGPCRStructure Therapeutics2.2247 of 5 stars$23.10+6.2%$81.29+251.9%-31.5%$1.32BN/A-31.22136Upcoming EarningsNews CoverageHigh Trading VolumeMESOMesoblast1.9176 of 5 stars$10.28-4.1%$18.00+75.1%+72.7%$1.31B$5.67M0.0080EVOEvotec1.8628 of 5 stars$3.58-0.6%$5.93+65.7%-19.1%$1.27B$777.05M0.004,200Upcoming EarningsShort Interest ↓Gap DownINDVIndivior3.3529 of 5 stars$8.81-2.2%$15.00+70.3%-34.5%$1.21B$1.19B-25.171,164Earnings ReportShort Interest ↑Analyst RevisionOCULOcular Therapeutix3.4863 of 5 stars$7.61+4.1%$16.38+115.2%+75.1%$1.21B$63.72M-5.77230Upcoming EarningsNews CoverageCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.5062 of 5 stars$23.50+0.6%$43.50+85.1%-40.8%$1.12B$731.97M7.831,620Upcoming EarningsPositive NewsARDXArdelyx4.5603 of 5 stars$4.56-5.4%$10.61+132.7%-13.9%$1.09B$333.62M-28.5090 Related Companies and Tools Related Companies Vera Therapeutics Competitors Travere Therapeutics Competitors Structure Therapeutics Competitors Mesoblast Competitors Evotec Competitors Indivior Competitors Ocular Therapeutix Competitors Calliditas Therapeutics AB (publ) Competitors Amphastar Pharmaceuticals Competitors Ardelyx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CKPT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
